- 专利标题: Designer Peptide Opsonins
-
申请号: US17348994申请日: 2021-06-16
-
公开(公告)号: US20210388031A1公开(公告)日: 2021-12-16
- 发明人: Dr. Vivek A. Kumar
- 申请人: New Jersey Institute of Technology
- 申请人地址: US NJ Newark
- 专利权人: New Jersey Institute of Technology
- 当前专利权人: New Jersey Institute of Technology
- 当前专利权人地址: US NJ Newark
- 主分类号: C07K14/005
- IPC分类号: C07K14/005 ; G16B15/00
摘要:
Disclosed is a new strategy, composition, and method for a self-assembling peptides (SAP) that will self-assemble atop COVID-19 for immune destruction and act as a functional COVID-19 opsonin. The designed self-assembling peptides bind and assemble atop SARS-CoV-2—providing a new mechanism of infection abrogation. One benefit is avoidance of side effects that other formulations or repurposed drugs contain. Other feature of this technology include: (a) (SAP) are composed of L-amino acids that are highly biocompatible sub-Q, IM and IV (no adverse reaction for 10% blood volume replacement with 1 w % peptide in mice or rats); (b) Highly targeted approach that binds to viral particles preventing side effects; (c) SAP are intrinsically biodegradable and endocytosed; (d) SAP bound COVID-19 may promote engulfment, clearance, and antigen presentation (for immunity development); and (e) targeting the spike protein with SAP may allow treatment of other coronaviruses.
信息查询